Interleukin-6, Tumor Necrosis Factor-α, and High-sensitivity C-reactive Protein in Diabetic Patients with Helicobacter pylori in Kosovo

  • Greta Begolli-Stavileci Medical Laboratory “Bioticus”, Prishtina, Kosovo
  • Gramos Begolli Department of Clinical Chemistry, Faculty of Medical, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia
  • Luljeta Begolli Department of Clinical Biochemistry, Faculty of Medicine, University of Pristina, Prishtina, Kosovo
Keywords: Helicobacter Pylori, IL-6, TNF- α, hs-CRP, CHD

Abstract

Helicobacter pylori is a Gram-negative spiral-shaped bacterium that infects from 30% to 50% of the world’s population and it is one of the most important in dyspeptic syndrome causes of gastritis and peptic ulcer. H. pylori is one of the most common chronic bacterial infections especially in the development countries because the socioeconomic contribute to chronic disease. The infection induces an acute polymorphonuclear infiltration in the gastric mucosa. Infection with H. pylori has been epidemiologically linked to some extra digestive conditions, including ischemic heart disease, diabetes mellitus (DM), and others. The patients with DM are at risk for H. pylori infection, since they have coupled susceptibility of to a wide range of infections as a result of chronic elevation of blood glucose level and impairment of immune functions. Chronic inflammation is a risk factor for coronary heart disease, because inflammation, vascular injury and thrombosis are considered to cause atherosclerosis. The risk of cardiovascular events is associated with increased levels of the acute phase proteins, C-reactive protein (CRP), and pro-inflammatory cytokines. Interleukin 6 (IL-6), a major pro-inflammatory cytokine is produced in a variety of tissues, including activated leukocytes, adipocytes, and endothelial cells. CRP is the principal downstream mediator of the acute phase response and is primarily derived through IL-6-dependent hepatic biosynthesis. Tumor necrosis factor-α (TNF-α), as an important inflammatory factor, has been shown to play a central role in the pathogenesis of diabetes. CRP and IL-6 were determinant of risk for the development of type 2 DM in apparently healthy middle-aged women. Since the prevalence of infected persons with H. pylori in Kosovo is high, the aim of this study was the evaluation of cytokines (IL1, TNF-α) and CRP in diabetic type 2 patients with positive H. pylori.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Kannan M, Ramani R, Kumar EK. Prevalence of Helicobacter pylori in relation to socioeconomic status. Int J Sci Res. 2019;8(3):1802-4. Available from: http://worldwidejournals.co.in/index.php/ijsr/article/view/1802/1804.

Suzuki H, Franceschi F, Nishizawa T, Gasbarrini A. Extragastric manifestations of Helicobacter pyloriinfection. Helicobacter. 2011;16 Suppl 1:65-9. https://doi.org/10.1111/j.1523-5378.2011.00883.x PMid:21896088

Samaropoulos XF, Light L, Ambrosius WT, Marcovina SM, Probstfield J, Goff DC Jr. The effect of intensive risk factor management in Type 2 diabetes on inflammatory biomarkers. Diabetes Res Clin Pract. 2012;95(3):389-98. https://doi.org/10.1016/j.diabres.2011.09.027 PMid:22019270

Peach HG, Barntt NE. Helicobacter pylori infection and fasting plasma glucose concentracio. J Clin Pathol. 2001;54:466-9.

Rahman A, Cope MB, Sarker SA, Garvey WT, Chaudhury HS, Khaled MA. Helicobacter pylori infection and inflammation: Implications for pathophysiology of diabetes mellitus and coronary heart disease. J Life Sci. 2009;1(1):45-50. https://doi.org/10.1080/09751270.2009.11885133 PMid:22308070

Ojetti V, Pellicano R, Fagoonee S, Migneco A, Berrutti M, Gasbarrini A. Helicobacter pylori infection and diabetes. Minerva Med. 2010;101(2):115-9. PMid:20467410

Diomedi M, Stanzione P, Sallustio F, Leone G, Renna A, Misaggi G, et al. Cytotoxin-associated gene-a-positive Helicobacter pylori strains infection increases the risk of recurrent atherosclerotic stroke. Helicobacter. 2008;13(6):525-31. https://doi.org/10.1111/j.1523-5378.2008.00627.x PMid:19166418

Hamed SA, Amine NF, Galal GM, Helal SR, Tag El-Din LM, Shawky OA, et al. Vascular risks and complications in diabetes mellitus: The role of Helicobacter pylori infection. J Stroke Cerebrovasc Dis. 2008;17(2):86-94. https://doi.org/10.1016/j.jstrokecerebrovasdis.2007.10.006 PMid:18346651

Ishida Y, Suzuki K, Taki K, Niwa T, Kurotsuchi S, Ando H, et al. Significant association between Helicobacter pylori infection and serum C-reactive protein. Int J Med Sci. 2008;5(4):224-9. https://doi.org/10.7150/ijms.5.224 PMid:19230307

Pickup JC, Chusney GD, Thomas SM, Burt D. Plasma interleukin-6, tumour necrosis factor alpha and blood cytokine production in Type 2 diabetes. Life Sci. 2000;67(3):291-300. https://doi.org/10.1016/s0024-3205(00)00622-6 PMid:10983873

Hu FB, Meigs JB, Li TY, Rifai N, Manson JE. Inflammatory markers and risk of developing Type 2 diabetes in women. Diabetes. 2004;53(3):693-700. https://doi.org/10.2337/diabetes.53.3.693 PMid:14988254

Albaker WI. Helicobacter pylori infection and its relationship to metabolic syndrome: Is it a myth or fact? Saudi J Gastroenterol. 2011;17(3):165-9. https://doi.org/10.4103/1319-3767.80377 PMid:21546717

El Hadidy EH, Abdul-Aziz MY, Mokhtar AR. Helicobacter pyloriinfection and vascular complications in patients with Type2 diabetes mellitus.JTaibah Univ Med Sci. 2009;4(1):62-72. https://doi.org/10.1016/s1658-3612(09)70082-4

Gunji T, Matsuhashi N, Sato H, Fujibayashi K, Okumura M, Sasabe N, et al. Helicobacter pylori infection is significantly associated with metabolic syndrome in the Japanese population. Am. J Gastroenterol. 2008;103(12):3005-10. https://doi.org/10.1111/j.1572-0241.2008.02151.x PMid:19086952

Kowalski M. Helicobacter pylori (H. pylori) infection in coronary artery disease: Influence of H. pylori eradication on coronary artery lumen after percutaneous transluminal coronary angioplasty. The detection of H. pylori specific DNA in human coronary atherosclerotic plaque. J Physiol Pharmacol. 2001;52 Suppl 1:3-31. https://doi.org/10.1016/s1590-8658(01)80711-8 PMid:11795863

Bener A, Micallef R, Afifi M, Derbala M, Al-Mulla HM, Usman MA. Association between Type 2 diabetes mellitus and Helicobacter pylori infection. Turk J Gastroenterol. 2007;18(4):225-9. PMid:18080918

Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing Type 2 diabetes mellitus. JAMA. 2001;286(3):327-34. https://doi.org/10.1001/jama.286.3.327 PMid:11466099

Shelbaya S, Amer H, Seddik S, Allah AA, Sabry IM, Mohamed T, et al. Study of the role of Interleukin-6 and highly sensitive C-reactive protein in diabetic ephropathy in Type 1 diabetic patients. Eur Rev Med Pharmacol Sci. 2012;16:176-82. PMid:22428468

Nakagawa H, Tamura T, Mitsuda Y, Goto Y, Kamiya Y, Kondo T, et al. Significant association between serum interleukin-6 and Helicobacter pylori antibody levels among H. pylori-positive Japanese adults. Mediators Inflamm. 2013;2013:142358. https://doi.org/10.1155/2013/142358 PMid:24453409

Howard BV, Best L, Comuzzie A, Ebbesson SO, Epstein SE, Fabsitz RR, et al. C-reactive protein, insulin resistance, and metabolic syndrome in a population with a high burden of subclinical infection: Insights from the genetics of coronary artery disease in Alaska natives (GOCADAN) study. Diabetes Care. 2008;31(12):2312-4 https://doi.org/10.2337/dc08-0815 PMid:18796618

Aydemir S, Bayraktaroglu T, Sert M, Sokmen C, Atmaca H, Mungan G, et al. The effect of Helicobacter pylori on insulin resistance. Dig Dis Sci. 2005;50(11):2090-3. https://doi.org/10.1007/s10620-005-3012-z PMid:16240220

Manco M, Putignani I, Bottazzo GF. Gut microbiota, lipopolysaccharides and innate immunity in the pathogenesis of obesity and cardiovascular risk. Endocr Rev. 2010;31(6):817-44. https://doi.org/10.1210/er.2009-0030 PMid:20592272

Fresno M1, Alvarez R, Cuesta N. Toll-like receptors, inflammation, metabolism and obesity. Arch Physiol Biochem. 2011;117(3):151-64. https://doi.org/10.3109/13813455.2011.562514 PMid:21599616

Devrajani BR, Shah SZ, Soomro AA, Devrajani T. Type 2 diabetes mellitus; A risk factor for Helicobacter pylori infection; A hospital based case-control study. Int J Diabetes Dev Ctries. 2010;30(1):22-6. https://doi.org/10.4103/0973-3930.60008 PMid:20431802

Nodoushan SA, Nabavi A. The Interaction of Helicobacter pyloriinfection and Type 2 diabetes mellitus. Adv Biomed Res. 2019;8:15. https://doi.org/10.4103/abr.abr_37_18 PMid:30993085

Nicholas SB, Kalantar-Zadeh K, Norris KC. Socioeconomic disparities in chronic kidney disease. Adv Chronic Kidney Dis. 2015;22(1):6-15. https://doi.org/10.1053/j.ackd.2014.07.002 PMid:25573507

Jeon CY, Haan MN, Cheng C, Clayton ER, Mayeda ER, Miller JW, et al. Helicobacter pylori infection is associated with an increased rate of diabetes. Diabetes Care. 2012;35(3):520-5. https://doi.org/10.2337/dc12-0440 PMid:22279028

Published
2020-05-10
How to Cite
1.
Begolli-Stavileci G, Begolli G, Begolli L. Interleukin-6, Tumor Necrosis Factor-α, and High-sensitivity C-reactive Protein in Diabetic Patients with Helicobacter pylori in Kosovo. Open Access Maced J Med Sci [Internet]. 2020May10 [cited 2020Oct.23];8(B):188-91. Available from: https://www.id-press.eu/mjms/article/view/3199